Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.

Summary, in English

To study frequency, possible baseline predictors, timing, and duration of sustained remission [SR; defined as 28-joint Disease Activity Score (DAS28) < 2.6 for at least 6 mos] in patients with established rheumatoid arthritis (RA) treated with different tumor necrosis factor (TNF) inhibitors [etanercept (ETN), infliximab (IFX), adalimumab (ADA)]. In addition, the aim was to compare (head-to-head) the effectiveness of individual drugs in patients receiving their first anti-TNF treatment.

• Author: Jon Thorkell Einarsson; Pierre Geborek; Tore Saxne; Meliha C Kapetanovic
• Department/s: Rheumatology
• Publishing year: 2015
• Language: English
• Pages: 741-748
• Publication/Series: Journal of Rheumatology
• Volume: 42
• Issue: 5
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25684762?dopt=Abstract; http://dx.doi.org/10.3899/jrheum.131502
• Document type: Journal article
• Publisher: Journal of Rheumatology Publishing Company Limited
• Topic: Rheumatology and Autoimmunity
• Status: Published
• ISBN/ISSN/Other: ISSN: 0315-162X